Blau Farmacêutica Balance Sheet Health
Financial Health criteria checks 6/6
Blau Farmacêutica has a total shareholder equity of R$1.9B and total debt of R$205.9M, which brings its debt-to-equity ratio to 11%. Its total assets and total liabilities are R$2.5B and R$630.2M respectively. Blau Farmacêutica's EBIT is R$364.3M making its interest coverage ratio -9.7. It has cash and short-term investments of R$391.7M.
Debt to equity ratio
|Interest coverage ratio||-9.7x|
Recent financial health updates
What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their EstimatesMay 14
Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen NextFeb 24
Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is UnlikelyOct 14
Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)Aug 17
Financial Position Analysis
Short Term Liabilities: BLAU3's short term assets (R$1.4B) exceed its short term liabilities (R$343.3M).
Long Term Liabilities: BLAU3's short term assets (R$1.4B) exceed its long term liabilities (R$286.9M).
Debt to Equity History and Analysis
Debt Level: BLAU3 has more cash than its total debt.
Reducing Debt: BLAU3's debt to equity ratio has reduced from 154.4% to 11% over the past 5 years.
Debt Coverage: BLAU3's debt is well covered by operating cash flow (127.4%).
Interest Coverage: BLAU3 earns more interest than it pays, so coverage of interest payments is not a concern.